Navigation Links
Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
Date:10/29/2007

ese statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties.

The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness; competitive factors in the industry in which we operate; our ability to protect our intellectual property; a delay in qualifying our manufacturing facility to produce our products or production or regulatory problems with either third party manufacturers upon whom we may rely for some of our products or our own manufacturing facility; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; an increase in litigation, including product liability claims and patent litigation; government regulation affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our a
'/>"/>

SOURCE Warner Chilcott Company, Inc.; Watson Pharmaceuticals,Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Charter and Time Warner to partner on fiber optics
2. Deltanoid Pharmaceuticals begins phase II osteoporosis study
3. The Coming of Biotech Generic Pharmaceuticals
4. Speaker announces business members of IT Task Force
5. Doyle announces technology tax credits for Berbee
6. Doyle announces new energy, global warming policies
7. Doyle, WARF announce partnership to lure stem cell companies
8. Doyle announces $80M renewable energy strategy
9. GE announces first installation of Discovery VCT
10. UWM announces winners of RGI awards
11. Third Wave announces two senior management appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Mechanicsburg, Pa (PRWEB) May 20, 2013 ... controller with ramp/soak capabilities. The 5R6-900 benchtop controller ... enclosure, the device can be plugged into the wall ... own power supply. This distinctive detail makes the device ... , The laboratory temperature controller can also be ...
(Date:5/20/2013)... Today, at the American Psychiatric Association (APA) ... James McGough , M.D., M.S., principal investigator ... for Neuroscience and Human Behavior and David ... of California Los Angeles (UCLA), and director of clinical ... ADHD at UCLA, presented the results of a Phase ...
(Date:5/20/2013)... DIEGO , May 20, 2013  Dr. ... field of nucleic acid research, recently launched a new ... In with Zon ( zon.trilinkbiotech.com ), focuses on what,s ... include interviews with industry thought leaders, discussions of research ... and more. Dr. Zon (PhD Princeton ...
(Date:5/20/2013)... 20, 2013 With bed bugs' presence come ... although bed bugs need to be eliminated, one must make ... a person's health. And so to help bed bug sufferers ... get rid of bed bugs without using harmful pesticides. ... spray it called Bed Bug Bully. , According to My ...
Breaking Biology Technology:New Laboratory Temperature Controller by Oven Industries 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies 2New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2
... BIRMINGHAM, Ala., Sept. 19 BioCryst,Pharmaceuticals, Inc. ... findings,from a Phase II study with intramuscular ... for the treatment of seasonal and,life-threatening influenza. ... The study was a randomized, double-blind, placebo-controlled ...
... ,Arpida Ltd (SWX: ARPN) presented a large body ... iclaprim at the 47th annual Interscience,Conference on Antimicrobial ... major scientific conference where thousands of scientists and,clinicians ... the latest,developments in the field of infectious diseases. ...
... bacterial contamination in ... platelets, WORCESTER, ... for detecting bacterial contaminants in,blood cells and tissue, has received 510 (k) ... Administration (FDA). This provides,Verax authorization to market the device, which cuts the ...
Cached Biology Technology:BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 2BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 3BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 4BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 5BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 6BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 7Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 2Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 3Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 4Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test 2Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test 3
(Date:5/20/2013)... of Minnesota Medical School researchers from the Masonic Cancer ... Brain Tumor Program, have developed a new mouse model ... them to discover new genes and gene pathways driving ... this week in the journal Nature Genetics . ... the lab of David Largaespada, Ph.D., professor in the ...
(Date:5/20/2013)... 20, 2013) - A novel vaccine study ... groundbreaking research that will be unveiled at the American ... The meeting takes place Monday, May 20 - Wednesday, ... Marina. , "The main goal of a vaccine ... a pathogen that causes the disease", explained Dr. Hemachand ...
(Date:5/19/2013)... Scientists at the University of California, Davis have engineered ... need for light. They report their findings today ... for Microbiology. , "In this work, we used synthetic ... on carbon dioxide and light energy for growth) cyanobacterial ... says Jordan McEwen, the lead researcher on the study. ...
Breaking Biology News(10 mins):U of M researchers develop model for better testing, targeting of MPNST 2Germ-fighting vaccine system makes great strides in delivery 2
... University have developed a technique that uses a ... particles within seconds, representing a potential new tool ... nanoassembly. The technique, called rapid electrokinetic patterning, ... the patterns can be more quickly and easily ...
... Conn.Organizations in the United States that are at the ... not adapting enough to the dangers posed by rising ... half century of climate change that has already significantly ... widespread ecological and hydrological impacts, and despite a near ...
... (DFG, German Research Foundation) will launch ten new Collaborative ... next four years with a total of approximately 90 ... Centres will study the origins of diseases caused by ... and the human skin. Other topics include the optimisation ...
Cached Biology News:New holographic method could be used for lab-on-a-chip technologies 2New holographic method could be used for lab-on-a-chip technologies 3New holographic method could be used for lab-on-a-chip technologies 4Most US organizations not adapting to climate change 2Most US organizations not adapting to climate change 3From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 2From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 3From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 4From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 5From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 6From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 7
...
...
... The greater incorporation of Br-dUTP results in ... detected using a fluorescein-labeled anti-BrdU antibody. ... the kit to counterstain the total DNA. ... resulting in improved detection than found by ...
Mouse monoclonal antibody raised against a partial recombinant FBXO24. NCBI Entrez Gene ID = FBXO24...
Biology Products: